Efficacy and safety of once-daily levobunolol for glaucoma therapy. 1989

S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
University of Miami School of Medicine.

We studied the ocular hypotensive efficacy and safety of 0.5% levobunolol hydrochloride and 0.5% timolol maleate administered topically once daily for 3 months in 91 patients (46 in the levobunolol group and 45 in the timolol group) with primary or secondary open-angle glaucoma or ocular hypertension. In this randomized double-masked parallel clinical study, intraocular pressure (IOP) was successfully controlled in 78% of the patients who received levobunolol and 89% of those who received timolol. The overall mean decrease in IOP was 5.6 mm Hg (decrease of 23%) in the levobunolol group and 6.7 mm Hg (26%) in the timolol group, a nonsignificant difference. In both groups the overall mean IOP during treatment was significantly lower than the pretreatment value (p less than 0.001). For both treatment groups changes in heart rate and blood pressure were minimal. We conclude that both 0.5% levobunolol and 0.5% timolol administered once daily are effective and safe in lowering IOP in most patients with ocular hypertension or open-angle glaucoma.

UI MeSH Term Description Entries
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009798 Ocular Hypertension A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma. Glaucoma, Suspect,Hypertension, Ocular,Glaucomas, Suspect,Hypertensions, Ocular,Ocular Hypertensions,Suspect Glaucoma,Suspect Glaucomas
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002040 Levobunolol The L-Isomer of bunolol. AKBeta,Apo-Levobunolol,Betagan,Levobunolol Hydrochloride,Novo-Levobunolol,PMS-Levobunolol,Ultracortenol,Vistagan,W-7000A,ratio-Levobunolol,Apo Levobunolol,ApoLevobunolol,Novo Levobunolol,NovoLevobunolol,PMS Levobunolol,PMSLevobunolol,W 7000A,W7000A,ratio Levobunolol
D005260 Female Females
D005902 Glaucoma, Open-Angle Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris. Glaucoma Simplex,Glaucoma, Pigmentary,Glaucoma, Simple,Open-Angle Glaucoma,Chronic Primary Open Angle Glaucoma,Glaucoma, Compensated,Glaucoma, Compensative,Glaucoma, Open Angle,Glaucoma, Primary Open Angle,Glaucoma, Secondary Open Angle,Primary Open Angle Glaucoma,Secondary Open Angle Glaucoma,Compensated Glaucoma,Compensative Glaucoma,Open Angle Glaucoma,Open Angle Glaucomas,Open-Angle Glaucomas,Pigmentary Glaucoma,Simple Glaucoma,Simplex, Glaucoma,Simplices, Glaucoma
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
October 1986, American journal of ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
March 1986, American journal of ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
October 1987, American journal of ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
February 1988, Ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
March 2002, The AIDS reader,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
March 1992, Ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
January 2005, Japanese journal of ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
January 1989, Ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
July 1991, American journal of ophthalmology,
S I Rakofsky, and M Lazar, and Y Almog, and R P LeBlanc, and C Mann, and A Orr, and P F Lee, and B R Friedland, and G D Novack, and E P Kelley
May 1989, Ophthalmology,
Copied contents to your clipboard!